S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:PEAR

Pear Therapeutics (PEAR) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
125 shs
Average Volume
7.75 million shs
Market Capitalization
$4.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Pear Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
∞ Upside
$6.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.85) to ($0.50) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

See Top Rated MarketRank™ Stocks Here

PEAR stock logo

About Pear Therapeutics (NASDAQ:PEAR) Stock

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.


PEAR Stock News Headlines

September 25, 2023 | finance.yahoo.com
Pear Therapeutics, Inc. (PEARQ)
September 14, 2023 | axios.com
ADHD video game maker Akili shifts focus from prescription to OTC, lays off 40%
September 28, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 13, 2023 | bizjournals.com
Digital health startup Akili cuts staff by 40%, abandons prescription model
August 28, 2023 | benzinga.com
Shaping the Future of Medicine: Anticipated $17.7 Billion Digital Therapeutics Market by 2027
August 23, 2023 | msn.com
Former execs from defunct Pear Therapeutics start VC firm
July 27, 2023 | msn.com
Startups Struggle With Insurers Over Digital Treatments
July 3, 2023 | bizjournals.com
Biotech layoffs 2023: In Q2, more than 700 Boston-area life science jobs were cut
September 28, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
June 26, 2023 | forbes.com
Prescription Digital Therapeutics For Mental Health: What It Means For Doctors And Their Patients
June 22, 2023 | marketwatch.com
Digital Therapeutics (DTx) Market Research Report 2023 Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2030
June 20, 2023 | finance.yahoo.com
Nox Health Closes Acquisition of Somryst, the Only FDA-Cleared Digital Insomnia Treatment, From Pear Therapeutics
June 12, 2023 | bizjournals.com
BehaVR adds 3 executives to senior leadership team
June 8, 2023 | finance.yahoo.com
Global Digital Therapeutics [DTx] for Mental Health Market Size
June 8, 2023 | finance.yahoo.com
BehaVR Appoints Former Pear Therapeutics, TytoCare and AVIA Executives to Senior Leadership Team
May 22, 2023 | axios.com
Pear Therapeutics sold for parts
May 16, 2023 | marketwatch.com
Digital Therapeutics Market 2023 Industry Trends, Growth, Size, Segmentation, Opportunities and Revenue by Forecast to 2031
May 14, 2023 | markets.businessinsider.com
Chardan Capital Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)
May 9, 2023 | markets.businessinsider.com
Seres Therapeutics (MCRB) Gets a Buy from Chardan Capital
May 9, 2023 | investing.com
Pear Therapeutics Inc (PEARQ)
May 5, 2023 | markets.businessinsider.com
Chardan Capital Remains a Buy on Omega Therapeutics (OMGA)
May 4, 2023 | markets.businessinsider.com
Chardan Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
May 3, 2023 | wsj.com
Firm Retention Summary: Pear Therapeutics
April 29, 2023 | marketwatch.com
Digital Therapeutics (DTx) Market Growth Strategies, Size, Geography Trends and Competitive Analysis to 2030
April 17, 2023 | finance.yahoo.com
It's Down 82% But Pear Therapeutics, Inc. (NASDAQ:PEAR) Could Be Riskier Than It Looks
April 14, 2023 | msn.com
Why Navidea Biopharmaceuticals Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
April 14, 2023 | msn.com
Why Is Pear Therapeutics (PEAR) Stock Down 26% Today?
See More Headlines
Receive PEAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PEAR Company Calendar

Today
9/28/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Health services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PEAR
CUSIP
N/A
CIK
1835567
Web
peartherapeutics.com
Phone
617-925-7848
Fax
N/A
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.00
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-75,490,000.00
Net Margins
-594.70%
Pretax Margin
-594.70%
Return on Equity
-217.85%
Return on Assets
-95.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.48
Quick Ratio
1.48

Sales & Book Value

Annual Sales
$12.69 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.22 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
142,739,000
Free Float
98,918,000
Market Cap
$4.17 million
Optionable
Not Optionable
Beta
0.45
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Corey M. McCann M.D. (Age 43)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $702.45k
  • Mr. Christopher D. T. Guiffre J.D. (Age 55)
    M.B.A., MBA, CFO, COO, Treasurer & Assistant Sec.
    Comp: $564.37k
  • Ms. Julia M. Strandberg M.B.A. (Age 48)
    Chief Commercial Officer
    Comp: $582.43k
  • Mr. Ronan P. O'Brien J.D. (Age 50)
    Chief Compliance Officer, Gen. Counsel & Sec.
  • Ms. Meara Murphy
    Sr. Director of Corp. Communications
  • Dr. Yuri Maricich M.B.A. (Age 43)
    M.D., Chief Medical Officer & Head of Devel.
  • Mr. Chris Valosky M.B.A.
    VP of Sales
  • Ms. Katherine Jeffery M.Sc. (Age 56)
    Chief People Officer
  • Ms. Erin K. Brenner (Age 50)
    Chief Product Devel. Officer
  • Ms. Ellen E. Snow CPA (Age 50)
    CGMA, VP & Corp. Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PEAR Stock - Frequently Asked Questions

Should I buy or sell Pear Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pear Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PEAR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PEAR, but not buy additional shares or sell existing shares.
View PEAR analyst ratings or view top-rated stocks.

What is Pear Therapeutics' stock price forecast for 2023?

4 equities research analysts have issued twelve-month target prices for Pear Therapeutics' stock. Their PEAR share price forecasts range from $5.00 to $8.00. On average, they predict the company's stock price to reach $6.67 in the next twelve months.
View analysts price targets for PEAR or view top-rated stocks among Wall Street analysts.

What is Pear Therapeutics' stock symbol?

Pear Therapeutics trades on the NASDAQ under the ticker symbol "PEAR."

Who are Pear Therapeutics' major shareholders?

Pear Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%). Insiders that own company stock include 5Am Partners Iv, Llc, Christopherd T Guiffre, Corey Mccann, Ellen Snow and Ronan O'brien.
View institutional ownership trends.

How do I buy shares of Pear Therapeutics?

Shares of PEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Pear Therapeutics make?

Pear Therapeutics (NASDAQ:PEAR) has a market capitalization of $0.00 and generates $12.69 million in revenue each year. The company earns $-75,490,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Pear Therapeutics have?

The company employs 300 workers across the globe.

How can I contact Pear Therapeutics?

Pear Therapeutics' mailing address is 195 CHURCH STREET 15TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is peartherapeutics.com. The company can be reached via phone at 617-925-7848 or via email at meara.murphy@peartherapeutics.com.

This page (NASDAQ:PEAR) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -